Group 1 - The China Securities Regulatory Commission (CSRC) has disclosed requirements for supplementary materials regarding overseas issuance and listing, specifically requesting Chengyi Biotechnology to clarify compliance related to its equity structure and reverse mergers [1] - The CSRC requires the company to explain whether shareholders holding more than 5% have fulfilled foreign exchange registration and whether domestic institutional shareholders have complied with external investment regulatory procedures [1] - The CSRC also demands details on the pricing, tax payments, and compliance with regulations during the acquisition of domestic entities, particularly in the context of red-chip structure establishment [1] Group 2 - Regarding the equity situation, the CSRC has requested clarification on whether the shareholding ratio of Hangzhou AstraZeneca Zhongjin and AstraZeneca UK Limited should be consolidated and if it meets the standards for shareholders holding more than 5% [2] - The CSRC seeks detailed arrangements concerning special shareholder rights, particularly the selection rights of directors and observers, and any changes in control before and after listing [2] - The CSRC requires a conclusive opinion on whether there has been any unfair pricing for new shareholders in the past 12 months and whether there are any issues related to interest transfer in equity incentives [2]